Biochemical markers of iron status and iron accumulation in peritoneal dialysis patients treated with ferric citrate
Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis · 2024
DOI: 10.1177/08968608231197361 ↗Kurz gefasst
Fachartikel in der Zeitschrift Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis, 2024. Verfasst von José E Navarrete und 2 weiteren Autor:innen. Beteiligte Einrichtung: Renal Division, Emory University School of Medicine, USA. Hauptthemen laut MEDLINE: Peritoneal Dialysis, Hyperphosphatemia, Acetates, Ferric Compounds. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Abstract (Originalsprache)
Background
Hyperphosphataemia is a common complication of kidney disease. Current dialysis techniques do not provide enough phosphorus clearance, hence the need to use phosphorus binders. Treatment options include calcium carbonate, calcium acetate, lanthanum carbonate, sevelamer hydrochloride and iron-based binders. Patients receiving peritoneal dialysis (PD) with sustained elevated ferritin levels exceeding 800 ng/mL are at a higher risk of death. We identify PD patients treated with iron-based binders and compare ferritin and risk of iron accumulation to patients treated with non-iron-based binders.
Methods
All records of patients receiving PD at Emory dialysis centres until 30 October 2021 were reviewed for phosphorus binders. Basic demographics and laboratory data were time-referenced to the days on treatment with a particular binder. Patients were followed until discontinuation of the phosphorus binder, death, transplant, transfer to another dialysis provider or censoring at 36 months after medication was started.
Results
Compared to calcium acetate and sevelamer, ferric citrate utilisation in PD patients resulted in a sustained increase in ferritin. The proportion of patients with a ferritin equal to or greater than 800 ng/dL and transferrin saturation greater than 40% increased over time in patients treated with ferric citrate and was higher during the second and third year of follow-up compared to baseline values and to patients treated with calcium acetate or sevelamer. Two patients (7%) treated with ferric citrate developed clinically significant haemosiderosis.
Conclusions
Use of ferric citrated in PD resulted in significant iron accumulation as judged by ferritin levels.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Renal Division, Emory University School of Medicine, USA.
Zitieren
APA
Navarrete, J. E., Ajiboye, O., & Lea, J. I. (2024). Biochemical markers of iron status and iron accumulation in peritoneal dialysis patients treated with ferric citrate. Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis. https://doi.org/10.1177/08968608231197361
Vancouver
Navarrete JE, Ajiboye O, Lea JI. Biochemical markers of iron status and iron accumulation in peritoneal dialysis patients treated with ferric citrate. Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis. 2024. doi:10.1177/08968608231197361
BibTeX
@article{Navarrete2024,
author = {Navarrete, José E and Ajiboye, Oyintayo and Lea, Janice I},
title = {Biochemical markers of iron status and iron accumulation in peritoneal dialysis patients treated with ferric citrate},
journal = {Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis},
year = {2024},
doi = {10.1177/08968608231197361}
}
EUVIMED